Aster DM Healthcare is trading around ₹632–₹634 as of September 4, 2025, and has shown solid resilience and upward movement over recent sessions. The company’s market capitalization stands at about ₹32,122 crore, and its current price-to-book ratio is roughly 9.4, reflecting growth expectations and sector strength.[1][2][3]
Recent financial results highlight substantial improvement: Q1 FY26 revenue reached ₹1,078 crore, up 8% year-on-year, and consolidated net profit for the quarter is ₹85.52 crore, maintaining momentum following last year’s major gains from the strategic disposal of its Gulf business. The EBITDA margin for FY25 has strengthened, averaging 19.5%, due to increased patient volumes and operational efficiency. For the whole of FY25, revenue grew 12% to ₹4,138 crore, and net profit posted a strong jump to over ₹5,400 crore with strategic gains from the GCC business separation.[4][5][6][7][8]
Balance sheet analysis shows rising book value and a stable asset base, indicating ongoing capital investment and sector expansion. Total expenses have grown moderately, while EBIT and PAT both reflect favorable YoY growth, with EBIT up 30% for the recent period. Trading volumes are steady, and the price action is currently above key moving averages, supporting a bullish technical outlook.[9][2][10][7][11]
Aster DM Healthcare’s positive trend is backed by solid quarterly results, sector tailwinds, and strategic realignment of its international operations. Investors remain optimistic for further medium-term gains if the company sustains improved margins and expanding patient demographics.
Recent financial results highlight substantial improvement: Q1 FY26 revenue reached ₹1,078 crore, up 8% year-on-year, and consolidated net profit for the quarter is ₹85.52 crore, maintaining momentum following last year’s major gains from the strategic disposal of its Gulf business. The EBITDA margin for FY25 has strengthened, averaging 19.5%, due to increased patient volumes and operational efficiency. For the whole of FY25, revenue grew 12% to ₹4,138 crore, and net profit posted a strong jump to over ₹5,400 crore with strategic gains from the GCC business separation.[4][5][6][7][8]
Balance sheet analysis shows rising book value and a stable asset base, indicating ongoing capital investment and sector expansion. Total expenses have grown moderately, while EBIT and PAT both reflect favorable YoY growth, with EBIT up 30% for the recent period. Trading volumes are steady, and the price action is currently above key moving averages, supporting a bullish technical outlook.[9][2][10][7][11]
Aster DM Healthcare’s positive trend is backed by solid quarterly results, sector tailwinds, and strategic realignment of its international operations. Investors remain optimistic for further medium-term gains if the company sustains improved margins and expanding patient demographics.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.